Opthea’s Post

Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, "Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD," underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with standard-of-care anti-VEGF-A therapies. Read press release here: https://lnkd.in/ez62P5NG We want to thank the authors: Ian Leitch Mike Gerometta David Eichenbaum @Robert Finger Nathan Steinle Megan Baldwin Access the full publication: https://lnkd.in/eu2-_Bdt #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

A new issue of the Journal of Ophthalmic and Vision Research (JOVR) is now available on KnE Publishing! JOVR is an Open Access journal with the mission to disseminate research, information, and viewpoints on different aspects of ophthalmology and vision science. Featuring 16 peer-reviewed articles, the latest issue explores key topics, such as: • Optogenetic therapy for retinal degenerative diseases • Management of acute optic neuritis • The relationship between night shift work and dry eyes Read the full issue >> https://lnkd.in/d4-BZqcw #OpenAccess #AcademicResearch #ResearchArticle #JOVR #VisionResearch #Ophthalmology

Is A Single Measurement Enough? – Why Spatial Considerations are Important in Diagnostic Tool in Age Related Macular Degeneration Guest Column Author: Meenakshi Kumar, M.Sc Clinical Ophthalmology and Vision Research (COVR) Doctoral Candidate, University of New South Wales Age related macular degeneration (AMD) is a progressive multifactorial senile ocular disease that remains an enigma with unknown causality. It is the major cause of vision loss worldwide. Read full article here: https://lnkd.in/giJRwtvW #AMDInsights #EyeHealth #MacularDegeneration #VisionCare #SpatialConsiderations #DiagnosticTools #Ophthalmology #EyeCare #MedicalResearch #HealthTech #Optometry #AgeRelatedMacularDegeneration #VisionScienceAcademy

As a passionate advocate for cutting-edge medical technology, I'm thrilled by the performance of RadiusXR, a game-changer in the field of visual field testing. 💡 Let's dive into the technical differentiators: 1️⃣ Precision Engineering: Unlike other virtual reality perimeters (VRPs) that repurpose consumer-grade gaming headsets, RadiusXR is meticulously designed and manufactured specifically for ophthalmology. This ensures optimal performance and reliability, giving clinicians the assurance they need in their diagnostic tools. 🔬 2️⃣ Unparalleled Accuracy: Our NOVA Clinical Trial has demonstrated a remarkable 0.94 correlation in mean deviation and statistical non-inferiority for glaucoma staging compared to traditional methods. This level of accuracy is a game-changer in diagnosing and managing ocular conditions, empowering clinicians with actionable insights to improve patient outcomes. 📊Read the peer-reviewed publication in the Journal of Translational Vision Science and Technology published by the Association for Research in Vision and Ophthalmology (ARVO). 3️⃣ Photopic Range Measurement: One of our key differentiators is our ability to measure vision within the photopic range, aligning perfectly with existing visual field platforms' standards. This ensures consistent clinical training and facilitates comparison to patients' prior examinations, ultimately enhancing outcomes. 🌟 4️⃣ Innovation in Action: RadiusXR is not just pushing boundaries but redefining them. This technology combines spatial computing with precision engineering to deliver unparalleled accuracy and reliability. From glaucoma staging to monitoring disease progression, RadiusXR is paving the way for a brighter future in ocular health. #RadiusXR #Innovation #OcularHealth #MedicalTechnology #VisionaryTech

A poster summarizing a clinical study with the innovative and revolutionary treatment of dry eye – RP501 – attracted great interest at the annual conference Association for Research in Vision and Ophthalmology, ARVO, in Seattle, USA. The poster was presented by Assoc. Prof. Dr. Gerhard Garhöfer, who was the principal investigator in the study. “I am very pleased with the positive response from the conference attendees, especially for the clinical results of the study which showed that RP501 has a unique mechanism of action and an innovative formulation that can help people suffering from mild to moderate dry eye. RP501 has strong potential to meet the high demand for clinical efficacy and ease of use that consumers demand,” says Assoc. Prof. Dr. Gerhard Garhöfer at the Medical University of Vienna. RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use – characteristics that consumers consider the most important parameters for a dry eye product. The study was completed in the spring of 2023 and is presented at ARVO under the title: “Assessment of safety, tolerability and efficacy of RP501 eye drops in patients with dry eye disease and subjects wearing contact lenses with lens discomfort.” #ARVO2024 #dryeyes #DED #innovation #RP501 #visionresearch #ophthalmology

🌟 At the forefront of ophthalmology: Dr. David Eichenbaum shares compelling results from a Phase IIB clinical trial at Retina World Congress. The study highlights Sozinibercept’s potential when combined with Ranibizumab, showing significant improvements in visual acuity for patients with specific types of macular lesions. This promising advancement could redefine treatment standards for neovascular macular degeneration by targeting both VEGF-A and additional pathways. #RWC2024 #OphthalmologyInnovation #ClinicalTrials Genentech Opthea RIWC24: Retina International World Congress 2024

Ophthalmology Science (June 2024 issue) published the paper “Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging System.” An in-depth review of the current scientific knowledge about different ways of taking pictures to check the blood vessels in the eyes of people with diabetic eye disease was conducted by the world’s experts to improve how we classify the disease in the future, identify deficiencies, and make recommendations for improvement. Professor Tien Yin Wong, MD, Co-Chair of MTM Vision’s Vascular Working Group, presided over the review written by Tien-En Tan, MBBS (Hons), FRCOphth, et al., for the DRD Staging System Update Effort, a project of MTM Vision. #Articles #Science #Research

Ophthalmology Science (June 2024 issue) published the paper “Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging System.” An in-depth review of the current scientific knowledge about different ways of taking pictures to check the blood vessels in the eyes of people with diabetic eye disease was conducted by the world’s experts to improve how we classify the disease in the future, identify deficiencies, and make recommendations for improvement. Professor Tien Yin Wong, MD, Co-Chair of MTM Vision’s Vascular Working Group, presided over the review written by Tien-En Tan, MBBS (Hons), FRCOphth, et al., for the DRD Staging System Update Effort, a project of MTM Vision. #Articles #Science #Research

https://lnkd.in/e_DMyWB2 Article title: Neuropeptide Research in the Eye   Author(s): Josef Troger*   Journal: Journal of Clinical Research and Ophthalmology   Journal ISSN: 2455-1414 Introduction: The neuropeptide research in the eye is the main topic of our scientific group in Innsbruck. Most of the neuropeptides have been discovered more than 30 years ago and the presence and distribution of some of them has been explored in the eye in the 80´s mainly by Richard Stone. This concerns particularly substance P (SP), calcitonin gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) and neuropeptide Y (NPY). Whereas SP and CGRP have been found to be constituents of the sensory innervation of the eye, VIP is present in the parasympathetic and NPY in the sympathetic innervation of the eye. #OphthalmologySubspecialties #Optometry #VisualScience #PharmacologyInEyeDiseases #BasicSciences #PrimaryEyeCare #SecondaryEyeCare #PatientSafety #QualityImprovements #NeuroOphthalmology #MedicalEyeCare #SurgicalEyeCare #GlaucomaFilteringProcedure #OcularDrugDesign #ClinicalPsychophysics #DiabeticRetinopathy #CataractSurgery #RefractiveSurgery #PVRStudies #LowVision #PterygiaStudies #PupilLightReflex #Peertechz #PeertechzPublications #SecondaryCataractStudies #RetinalDiseases #RetinalSurgery #SubstancePStudies #Cornea #ExternalEyeDisease #DefensinsForCorneaTransplants #CraniofacialClinic #OptometryClinic #OphthalmicGeneticsClinic #NeuroOphthalmologyClinic #Oculoplastics #TearingDisordersClinic #PediatricRetinaClinic #CornealNeovascularization #ImmunologicalMechanisms #MolecularMechanisms #LaserTherapyInOphthalmology #ImagingInOphthalmology #OcularImmunology #VisionAndOphthalmology #NeuroOphthalmology

👀 Geographic atrophy (GA) is one of the characteristics of advanced age-related macular degeneration (AMD) and can cause vision loss, even legal blindness. Yet, treatment options for GA or its progression remain limited. This NEI research investigated minocycline's potential to slow vision loss and halt GA expansion in AMD patients. Our VeriSee AMD, a TFDA-approved medical AI, makes early screening for AMD and early access to ophthalmic care possible. Together, we can improve public health of eye care! #AMD #GeographicAtrophy #EyeHealth #NEI #AcerMedical #VeriSeeAMD